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Biomarkers for multiple sclerosis determined by metabolomic profiling using 
coupled UPLC-MS  
Sean Ward, Michael I. Page and Nicholas T. Powles 
 
The project aim was to identify differences in the metabolomic profiles in the serum of patients with 
multiple sclerosis (MS), those with neuropathic pain (NP) and those with both MS and NP 
compared with controls and to identify potential biomarkers of each disease state. Metabolomic 
profiling was performed using ultra-high-performance liquid chromatography coupled to mass 
spectrometry and the data analysis involved parametric methods, principal component analysis, and 
discriminating filter analysis to determine the differences between disease and control serum 
samples.  
Agilent software Profinder and Mass Profiler Professional (MPP) were used to compare LC-MS 
data generated from the blood plasma of people suffering with multiple sclerosis with an age and 
gender matched control group. This was an un-targeted approach which led to the discovery of two 
compounds, sphingosine and dihydrosphingosine that were found to be lower in the blood of people 
suffering from multiple sclerosis. These compounds were searched in a larger sample set and found 
to follow the same trend of being lower in the disease group. It may be possible to use the 
concentration of these compounds in the blood as a marker of the disease. 
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Supplementary Information 
Biomarkers for multiple sclerosis determined by metabolomic profiling using 
coupled UHPLC-MS  
Sean Ward,  Michael I. Page
 
and Nicholas T. Powles 
Figure 1 PCA plot of raw data in MPP for plasma analysis of multiple sclerosis (blue), 
neuropathic pain (grey), multiple sclerosis and neuropathic pain (brown), control group 
(red) and QC injections (green). The principle component is plotted on the X-axis and 
represents 17% of data variation. Component 2 on the Y-axis represents 11% of the 
variation and component 3 on the Z-axis 6% of the variation. 
 
 
Figure 2 PCA plot of re-processed data in MPP for plasma analysis of multiple sclerosis 
(blue), neuropathic pain (grey), multiple sclerosis and neuropathic pain (brown), control 
group (red) and QC injections (green). The principle component is plotted on the X-axis and 
represents 27% of data variation. Component 2 on the Y-axis represents 13% of the 
variation and component 3 on the Z-axis 7% of the variation. 
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Figure 3 An example of a missed integration in 7/10 samples in Profinder of compound m/z 
805.0323. 
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Figure 4 EIC of m/z 300.2892 in control group sample showing the presence of two 
compounds with that m/z.  
 
 
Figure 5. Isotope fit for formula C18H37NO2 eluting at 21.3min in control group sample 
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 Figure 6. EIC’s of m/z 300.2892 in control sample and sphingosine spiked control sample 
showing peak alignment for peak eluting at 21.4min. 
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Figure 7. Fragmentation pattern for m/z 300.2892 in control group sample. 
 
Figure 8.  Fragmentation pattern for m/z 300.2892 in sphingosine standard. 
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Figure 9 Abundance of sphingosine in the multiple sclerosis, neuropathic pain, multiple sclerosis with neuropathic pain and control group. 
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Figure 10. EIC’s of m/z 302.30536 in dihydrosphingosine, control sample and spiked control sample. 
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Figure 11. Fragmentation pattern for m/z 302.30536 in control and dihydrosphingosine standard sample. 
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Figure 12. Sphingosine peak area for large sample set of control (blue), multiple sclerosis (red) and multiple sclerosis with neuropathic pain 
(green) groups. 
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Table: Multiple sclerosis LC-MS conditions 
HPLC-MS 
Instrument 6530 Q-TOF 
Column C18 1.8um 2.1X100mm 
Oven (ºC) 35 
Pump Mobile Phase A Water 0.1% formic acid 
Mobile Phase B Acetonitrile 0.1% formic acid 
Flow (ml/min) 0.5 
Isocratic/Gradient Gradient 
 Time/min %A %B 
0.00 98 2 
1.00 98 2 
30.00 0 100 
35.00 0 100 
35.1.10 98 2 
40.00 98 2 
Runtime (min) 40 
Injector Volume (ul) 10 
Detector Wavelength 
Reference 
N/A 
MS QTOF/QQQ QTOF/QQQ QTOF Mode positive 
Source 
Duel jet stream 
Electrospray 
Gas temp 
(oC) 
300 Gas flow 
(l/min) 
8 
Sheath 
gas temp 
(oC) 
350 Sheath gas 
flow 
(l/min) 
10 
Nebuliser 
pressure 
(psig) 
35   
VCap (V) 3750 Fragmentor 
(v) 
175 
Nozzle 
Voltage 
(V) 
1000   
Mass 
range 
100-
1700 
Acquisition 
rate 
(Scans/s) 
3 
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Biomarkers for multiple sclerosis determined by metabolomic profiling using 
coupled UPLC-MS  
Sean Ward, Michael I. Page and Nicholas T. Powles 
 
The project aim was to identify differences in the metabolomic profiles in the serum of patients with 
multiple sclerosis (MS), those with neuropathic pain (NP) and those with both MS and NP 
compared with controls and to identify potential biomarkers of each disease state. Metabolomic 
profiling was performed using ultra-high-performance liquid chromatography coupled to mass 
spectrometry and the data analysis involved parametric methods, principal component analysis, and 
discriminating filter analysis to determine the differences between disease and control serum 
samples.  
Agilent software Profinder and Mass Profiler Professional (MPP) were used to compare LC-MS 
data generated from the blood plasma of people suffering with multiple sclerosis with an age and 
gender matched control group. This was an un-targeted approach which led to the discovery of two 
compounds, sphingosine and dihydrosphingosine that were found to be lower in the blood of people 
suffering from multiple sclerosis. These compounds were searched in a larger sample set and found 
to follow the same trend of being lower in the disease group. It may be possible to use the 
concentration of these compounds in the blood as a marker of the disease. 
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Sphingosine and dihydrosphingosine as biomarkers for multiple 
sclerosis identified by metabolomic profiling using coupled UPLC-
MS  
Sean Ward,
a
  Michael I. Page,
a
 Patrick McHugh
a
 and Nicholas T. Powles
a*
 
The project aim was to identify differences in the metabolomic profiles in the serum of patients with multiple sclerosis 
(MS), those with neuropathic pain (NP) and those with both MS and NP compared with controls and to identify potential 
biomarkers of each disease state. Metabolomic profiling was performed using ultra-high-performance liquid 
chromatography coupled to mass spectrometry and the data analysis involved parametric methods, principal component 
analysis, and discriminating filter analysis to determine the differences between disease and control serum samples. 
Sphingosine and dihydrosphingosine were identified as significant biomarkers. 
Introduction 
There is a long recorded history of people suffering from multiple 
sclerosis (MS) which spans back centuries before it was given its 
modern name. People who developed a progressive paralysis would 
be diagnosed as suffering from paraplegia, a general diagnosis 
which covered many different neurological disorders.
1
 In the 19
th
 
century physicians performing careful pathology started to become 
aware of scattered grey patches, scar tissue in the nervous systems 
of young adults with a specific progressive disorder
2
. MS is now 
known to be a disease caused by the immune system attacking the 
myelin insulation surrounding the nerve cells in the central nervous 
system (CNS) causing the nerve impulses to slow down and 
eventually stop.
3
 Because the effects of this nerve damage do not 
become evident until substantial damage has occurred people in 
the early stages of the disease often appear healthy. Myelin is made 
in the oligodendrocytes and its dry mass is composed about 70–
85% lipids and about 15–30% proteins which allow it to stick only to 
a specific axon and insulate it.  The CNS is isolated from the rest of 
the body by the blood brain barrier, reinforced by astrocytes which 
allow the transport of immune cells into the central nervous 
system.
3
 Most of the cells in the body produce distinctive molecules 
that serve to identify them as being “self” and the immune system 
normally does not attack these cells. Auto immune diseases occur 
when the immune system wrongly identifies epitopes on self-cells 
as being foreign and launching an immune attack.
4
 Naturally 
occurring auto reactive myelin T cells are normally under the 
control of the regulatory T cells, but in multiple sclerosis this control 
is lost and the T cells attack the myelin producing oligodendrocytes. 
This loss of T cell regulation leads to the T cells becoming activated, 
proliferating and circulating throughout the body. These T cells then 
produce adhesion molecules and changes in the endothelia which 
in turn allow access into the CNS across the blood brain barrier.
5
 
The epidemiology of multiple sclerosis reveals two consistent 
features, that the disease clusters in families and that its frequency 
depends on which part of the world you live in, implying that there 
might be a genetic and an environmental component to the 
disease.
6
 The screening of the genome from tens of thousands of 
multiple sclerosis sufferers in comparison to a control group has 
revealed more than 100 common variables of genes in the MS 
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group, regularly found on genes which are involved in 
immunological processes and specifically in their regulatory 
regions.
6
 More than thirty years ago it was proposed that vitamin D 
deficiency was a risk factor for MS and it has been shown that 
vitamin D has an immunomodulatory effect and sufficient levels can 
help protect against MS.
7
 Vitamin D promotes the production of 
regulatory T cells which suppresses the presentation of antigens to 
the T helper cells also reducing the activation and recruitment of 
these cells.
8
 Women are more likely than men, with a ratio 3:1, to 
develop MS and women with MS often show signs of improvement 
during pregnancy and worsen after childbirth. Testosterone and 
estrogen have been shown to have anti-inflammatory effects in 
animal models of the disease.
9
  
In recent years evidence that environmental factors which may 
affect MS to the greatest extent seems to be related to the gut 
microbiota as MS sufferers have an increased risk of gut 
permeability and inflammatory bowel disease which suggests that 
there may be a connection between the gut and the CNS.
10
 It has 
also been shown that Pseudomonas peptides can activate myelin 
basic protein specific T cells which have been cloned from MS 
patients, but the difficulty in linking a specific microorganism with 
MS is that there are numerous microbial sequences that can 
activate the myelin basic protein specific T cells from MS patients.
11
 
Chlamydia pneumonia is commonly found in the cerebrospinal fluid 
of people suffering from MS and has been shown to induce the 
disease in an animal model.
12
 Finally, there have been proposed 
links with mitochondrial dysfunction and multiple sclerosis along 
with other neurological diseases such as Alzheimer’s and 
Parkinson’s
13
.  
In summary, the full understanding of the causes of MS is far from 
complete. The metabolomics analysis of pathways combined with 
the identification and quantification of small molecules in disease 
patients may help to solve this problem. Liquid chromatography 
mass spec (LC-MS) is growing in popularity in the field of 
metabolomics
14
 but is highly dependent on both the analytical 
method and data analysis steps.
15
 The use of metabolomics 
techniques has found metabolic differences between control 
groups and people with MS using GC-MS and LC-MS.
16
 Herein LC-
MS of blood plasma samples from people suffering with multiple 
sclerosis (MS), neuropathic pain (NP) and multiple sclerosis with 
neuropathic pain (MSNP) along with a control group was used to 
identify specific biomarkers which could be a useful diagnostic tool. 
Results 
For the comparison of LC-MS data sets the features first need to be 
extracted using their accurate mass and then be aligned by 
retention time.
17
 Feature extraction and data alignment is a critical 
step for the reduction of false positives and negatives and also 
reduces data file size and complexity by the removal of non-specific 
information and removing features based on their accurate mass 
and elution time. It is very important to produce good quality raw 
data for feature extraction because poorly resolved data can lead to 
an increase in false peak detection, missing values and incorrect 
identifications. 
Blood plasma samples from people suffering with (i) multiple 
sclerosis (MS), (ii) neuropathic pain (NP) and (iii) multiple sclerosis 
with neuropathic pain (MSNP) along with (iv) a control group were 
deproteinated by mixing 250µl of plasma with 1 ml of methanol, 
then centrifuged at 12000G for 5 min. before being filtered using 
syringe filters. Ten samples of each disease type and ten control 
samples were analysed along with quality control (QC) samples by 
taking equal portions of each sample and combining them. The 
samples were analysed by LC-MS on an Agilent 1290 HPLC 
combined with a 6530 Q-TOF. A dual jet stream ionisation source 
was used in positive mode using the LC and MS conditions given in 
the ESI. Because of the high number of samples and the complexity 
of the data it is difficult to check all of the compound integrations in 
the Profinder and Mass Profiler Professional (MPP) software. The 
workflow used was: 
 
 
 
 
For the initial data extraction very lenient filtering parameters were 
used in order to catch as much data as possible. A peak height cut-
off of 2000 total ion counts was used which was only six times the 
instrument noise level. The retention time drift in the QC samples 
Acquire  
MS data 
 Recursive extraction  
with wide filter 
 parameters 
 Compounds with 
 significant fold 
change and P-value 
 
Compounds from these 
integrations checked with 
narrower filter parameters 
 Identify compounds  
of interest 
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was 0.2 min but a retention time window of 0.5 min and a relatively 
large mass error window of 15 ppm. The use of these parameters 
yielded the detection of 3,494 compounds which were then further 
analysed, but with no further filtering at this stage. A volcano plot 
was used to find the differentiating compounds between the 
control group and the disease groups with a fold change above 2 
and satisfying a P-value of 0.05. Each of the three entity lists 
generated from the volcano plots were then combined to give the 
Venn diagram (Figure 1). 
    
Figure 1. Venn diagram of entity lists created with volcano plots 
between multiple sclerosis, neuropathic pain, multiple sclerosis 
with neuropathic pain and the control group. 
This entity list was then re-extracted, all of the integrations 
checked, the samples ordered by mass and duplicates removed to 
give 307 entities. Using principle component analysis of the re-
processed data, creating new volcano plots, again comparing the 
controls to each disease group, but this time using the Bonferroni 
FWER multiple testing correction, a P-value of 0.05 and a fold 
change of 2 for each sample set to give the new Venn diagram 
(Figure 2).  
There are 25 entities that differentiate the disease groups from the 
control group; 4 that only differ in the neuropathic pain group, 11 in 
the multiple sclerosis with neuropathic pain group and 1 entity that 
only differs in the multiple sclerosis group. There are 6 entities that 
differ in all of the disease groups and only 2 that differ in both the 
multiple sclerosis and neuropathic pain groups compared with the 
control group. There is just 1 entity that differs in both the multiple 
sclerosis and multiple sclerosis with neuropathic pain groups and 
this difference in the abundance of this entity is common to all of 
the samples collected from people with multiple sclerosis. 
 
 
Figure 2. Venn diagram of entity lists created with volcano plots of 
re-processed data between multiple sclerosis, neuropathic pain, 
multiple sclerosis with neuropathic pain and the control group. 
The 25 differentiating compounds were searched against the Metlin 
data base and formulae only matched if the mass error was less 
than 5ppm (ESI). The one compound which differentiates people 
suffering from multiple sclerosis compared with the control group 
has a mass of 299.2818 and elutes at 21.3min with the method 
used in this analysis. The extracted ion chromatogram for m/z 
300.2892 in a control group sample shows 2 peaks, one at 21.3min 
and one at 22.3min. The formula C18H37NO2 was generated for mass 
299.2818 eluting at 21.3min with good isotope fit. A possible 
structure for this is sphingosine (1), a component of sphingolipids. 
Sphingolipids are one of the well-defined lipid categories and their 
structural diversity and complexity involves N-acylation, O-
phosphorylation, O-glycosylation and conversion to ceramides, and 
sphingomyelin.
18
  As well as ensuring cellular membrane integrity
19
 
sphingolipids are play key roles in signaling and regulation of cell 
growth, proliferation, survival and apoptosis.
20
 Metabolic disorders 
involving sphingolipids
21
 include diabetes, cardiovascular diseases, 
various cancers
22
 as well as central nervous system disorders.
23
 
None of the other compounds in the 25 differentiating set had 
masses corresponding to readily identifiable blood plasma 
components. 
 
(1) sphingosine  
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A sample of plasma from one of the control group was de-
proteinated with (i) LC-MS grade methanol and (ii) LC-MS grade 
methanol spiked with 0.2 ppm sphingosine. These two samples 
were then analysed using the previously described methodology 
and their extracted ion chromatograms compared (Figure 3). The 
peaks for m/z 300.2892 have shifted slightly to the right because 
the column had not been fully conditioned and are now at 21.4min 
and 22.4min. The peak at 21.4min is much bigger and there are no 
extra peaks. This means that the unknown compound with mass 
299.2818 has the same mass isotope pattern and retention time as 
sphingosine. 
 
Figure 3. Extracted ion chromatograms of m/z 300.2892 in control 
sample and sphingosine spiked control sample showing peak 
alignment for peak eluting at 21.4 min. 
The control sample and the sphingosine sample were then analysed 
by MS/MS at collision energies of 10, 20 and 40eV. A shorter 15min 
LC gradient was used to reduce analysis time. The fragmentation 
patterns for both have major fragments with m/z’s of 282.278, 
264.268 and 252.267. These fragments also have the same relative 
abundance in both samples. The MS/MS spectra for the control 
group sample were then exported into a database which gave 
sphingosine as one of the top hits. The fragments for the three 
main ions are those expected by mono- and di- dehydroxylation. 
When the distribution of sphingosine was plotted across all disease 
groups (Figure 4) it appeared lowest in the neuropathic pain group 
compared with the control. In one of the replicates no sphingosine 
was detected.  
 
Figure 4. Abundance of sphingosine in the multiple sclerosis (MS), 
neuropathic pain (NP), multiple sclerosis with neuropathic pain 
(MSNP) and control group. 
A second identifying compound that differentiated both MS and 
MSNP from the control group was that eluting at 22.0min with mass 
301.2978 gives a good accurate mass and isotope pattern to the 
molecular formula C18H39NO2. The isotope fit is shown in figure 5 of 
ESI for the singly charged protonated adduct. Dihydrosphingosine 
(1,3-dihydroxy-2-aminooctadecan) is a possible compound for this 
formula with mass 301.2981 and is a naturally occurring compound 
found in blood. A commercial sample of dihydrosphingosine was 
analysed separately at a concentration of 0.2ppm. When a blood 
sample was spiked with dihydrosphingosine, it showed a single 
peak at the same retention time with increased intensity. The 
samples were then analysed by MS/MS at collision energies of 10, 
20 and 40eV with a shorter 15min LC gradient to reduce analysis 
time. The fragmentation patterns for dihydrosphingosine and the 
peak in the control at the same retention time have an identical 
pattern, with major fragments at 284.295, 254.284 and 60.045. The 
MS/MS spectra for the control group sample was then exported 
into the ChemSpider database which gave dihydrosphingosine as 
one of the top hits and the possible fragments for the three main 
ions corresponding to loss of OH, CH2O and [H2NCH2CHOH]
+
 as 
expected from the structure. 
In order to further investigate the difference in sphingosine 
concentrations between a multiple sclerosis group and a control 
group, a larger sample set was used. For this work 30 plasma 
samples from people with multiple sclerosis (15 of which also had 
neuropathic pain) were analysed along with 60 age and gender 
matched control samples. Sphingosine levels were significantly 
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lower in the multiple sclerosis groups compared with the control 
group giving p=6.06x10
-10
. The control group had a mean peak area 
of 18,990 and standard deviation of 6,286. The multiple sclerosis 
groups had mean peak areas of 9,535 for multiple sclerosis and 
11,254 for multiple sclerosis with neuropathic pain and standard 
deviations of 3,032 and 3,863, respectively.  The p-value for the 
difference between the MS and MSNP groups was 0.186 showing 
no significant statistical difference between the two MS groups. 
Similarly, the dihydrophingosine levels were significantly lower in 
the multiple sclerosis groups compared with the control group with 
p=4.89x10
-6
. The control group had a mean peak area of 7,723 and 
standard deviation of 2,345, whereas the multiple sclerosis groups 
had mean peak areas of 4,936 for MS and 5,904 for MSNP with 
standard deviations of 1,389 and 1,581, respectively.  The p-value 
for the difference between the MS and MSNP groups was 0.086 
showing no significant statistical difference between the two MS 
groups. 
Discussion 
Two compounds have been identified in this study as potential 
biomarkers for multiple sclerosis, sphingosine and 
dihydrosphingosine, which are found at significantly lower 
concentrations in both the multiple sclerosis and the multiple 
sclerosis neuropathic pain groups. These sphingolipids have an 
eighteen carbon amino alcohol backbone and variations in this basic 
structure create a wide variety of sphingolipids that are utilised in 
constructing cell membranes and for acting as signalling 
molecules
24
. Phosphorylation of sphingosine and 
dihydrosphingosene at the C1 hydroxyl group creates the important 
cellular signalling molecules sphingosine-1-phosphate and 
dihydrosphingosine-1-phosphate, respectively. Sphingosine is 
synthesised from the hydrolysis of sphingomyelin or from the 
precursors serine and palmitoyl-CoA.
25
   
Although a difference was anticipated between the neuropathic 
pain group and the multiple sclerosis/multiple sclerosis with 
neuropathic pain groups, with regards to levels of sphingosine and 
dihydrosphingosine the neuropathic pain group showed a similar 
trend as the multiple sclerosis/ MSNP groups indicating the 
possibility of underlying similar biochemical mechanisms in these 
three groups. Neuropathic pain can accompany multiple sclerosis as 
a result of de-myelination but not all cases of multiple sclerosis 
include neuropathic pain.
26
 
Neuropathic pain without multiple sclerosis is a debilitating 
condition with limited treatment potential due to its unknown 
biochemical basis. Recently an LC-MS metabolomics study was 
carried out on rats which had been subjected to tibial-nerve 
transection (TNT). The results of this study showed alterations in 
sphingomyelin-ceramide metabolism. This was due to an increase in 
the levels of the enzyme sphingomyelinase which is responsible for 
catalysing the breakdown of sphingomyelin to ceramide and 
phosphoryl choline. In this study both sphingosine and 
dihydrosphingosine levels were elevated
27
, in sharp contrast to the 
findings reported here conducted on human samples with real 
disease conditions. 
Another study
28
 found differences in lipid composition in the white 
and grey matter of multiple sclerosis patients. Patients with active 
multiple sclerosis showed higher levels of phosphorylated 
sphingolipid but lower sphingolipid levels in both white and grey 
matter. This is in agreement with the results found herein from 
blood plasma analysis. In patients with inactive multiple sclerosis 
only white matter had increased phosphorylation of sphingolipids. 
One of these was phosphatidylcholine which on hydrolysis yields 
lysophosphatidylcholine
29
 which can be used for the in vitro 
demyelination of nerve fibres
30
 which could be another contributing 
factor to the progression of the disease. 
The drug fingolimod (2) has shown promise in clinical trials for the 
treatment of multiple sclerosis. Fingolimod is a sphingosine 
analogue which is phosphorylated in the body to form fingolimod-
phosphate, this resembles sphingosine-1-phosphate (S1P). 
Currently five S1P receptors have been discovered (S1P1-5) which 
are found on a variety range of cell types including lymphocytes and 
neural cells. The immune and central nervous system has a large 
number of S1P1-3 receptors, S1P4 receptors are usually found on 
lymphoid and heamatopetic tissue and S1P5 receptors are found on 
the white matter of the central nervous system. The S1P receptors 
in the CNS could contribute to the neuropathology of multiple 
sclerosis effecting neurogenesis as well as neural function and 
migration
31
. 
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(2) 
Sphingolipids also play an important role in microbial pathogenesis 
regulating the balance between the microbe and the host. Most 
bacteria and viruses do not produce their own sphingolipids but 
instead use the sphingolipids of the host cell. The utilization of the 
host cells sphingolipids for the production of a microbial cellular 
membrane may be used by a microbe to hide from the immune 
system allowing colonisation. Alternatively the microbe may 
enzymatically functionalise the sphingolipid which may interfere 
with intracellular signalling thus avoiding removal and destruction 
from the host cell.
32
 
Conclusion 
The project aim was to identify differences in the metabolomic 
profiles in the serum of patients with multiple sclerosis (MS), those 
with neuropathic pain (NP) and those with both MS and NP (MSNP) 
compared with controls and to identify potential biomarkers of 
each disease state. We found that the concentration of both 
dihydrosphingosine and sphingosine are lower in all groups 
compared with those in the controls and so the detection of the 
differences in the concentrations of these compounds in blood 
plasma may be a useful diagnostic tool to aid in the investigation of 
their role in the disease. This was achieved using a fast analytical 
methodology. Sphingosine and dihydrosphingosine have been 
previously found to be at lower concentrations in the brain tissue of 
patients with multiple sclerosis. The detection of these 
sphingolipids in blood plasma is advantageous because it allows the 
non-invasive monitoring of these and related compounds. 
For this project the ability of MPP software to determine 
differences between disease groups and control groups quickly and 
easily was tested. Only reverse phase chromatography was used as 
this gave good separation of the detectable compounds present in 
the samples. For detection only Jet Stream ESI positive was used 
because this gave the largest number of compounds. The data 
processing is the most time consuming part of the MPP workflow so 
the data was first processed with Profinder then put into MPP 
unchecked. The data was filtered in MPP on fold change (2) and p-
value (0.05) and the generated compound list re-processed with 
Profinder. This drastically reduced the number of compounds that 
had to be manually checked for proper integration. This process 
reduced the data processing time from weeks to days. 
Experimental 
Blood plasma samples from people suffering with (i) multiple 
sclerosis (MS), (ii) neuropathic pain (NP) and (iii) multiple sclerosis 
with neuropathic pain (MSNP) along with (iv) a control group were 
deproteinated by mixing 250µl of plasma with 1 ml of methanol, 
then centrifuged at 12000G for 5 min. before being filtered using 
syringe filters. Ten samples of each disease type and ten control 
samples were analysed along with quality control (QC) samples by 
taking equal portions of each sample and combining them. The 
samples were analysed by LC-MS on an Agilent 1290 HPLC 
combined with a 6530 Q-TOF. A dual jet stream ionisation source 
was used in positive mode using the LC and MS conditions given in 
the ESI. Because of the high number of samples and the complexity 
of the data it was difficult to check all of the compound integrations 
in the Profinder and Mass Profiler Professional (MPP) software. 
To further investigate the difference in sphingosine concentration 
between a control group and a multiple sclerosis group a larger 
sample set was used consisting of 30 plasma samples from people 
with multiple sclerosis (15 of which also had neuropathic pain) were 
analysed along with 60 age and gender matched control samples 
and the peak area for sphingosine integrated using Profinder. 
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